Searched for
BIOCON BIOLOGICS MERGER
With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...- ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar ShawBiocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves...
- Biocon shares jump 3% to hit new 52-week high on $4.5 billion Biologics IPO, merger reviewBiocon shares hit a new 52-week high after the company confirmed it is evaluating a potential merger of Biocon Biologics with the parent en...
- Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under reviewBiocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...
- Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran ShawBiocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...
- Serum Life Sciences to double investments in Biocon Biologics to $300 million under new arrangementUnder the fresh terms of their strategic alliance, Serum Life Sciences will make an additional equity investment of $150 million through th...
- Stocks in news: Zee Entertainment, Hero MotoCorp, Biocon, Greaves CottonOrient Cement has entered into a non-binding agreement with Adani Power Maharashtra for setting out the understanding for facilitating bona...
- Stocks in the news: HDFC Bank, Hero Moto, PVR, Yes Bank and AstralThe multiplex operators, PVR and Inox Leisure, said that they have received clearances for their merger from bourses NSE and BSE. Both comp...
- CCI clears Serum Institute Life Sciences-Biocon Biologics dealOnce the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...
- Stocks in the news: RIL, Adani Enterprises, TCS, DLF, DMart and Tata PowerGNA Axles, 5Paisa Capital, Vikas Lifecare, Ganga papers India, Excel Realty and Add-Shop ERetail are among the companies that will announce...
- Stocks in the news: CMS Info, SBI, Biocon, RBL Bank, HUL and FSLCMS Info Systems will make its Dalal Street debut today. The company raised Rs 1,100 crore via primary route offering its shares in the ran...
- Can Serum deal provide a booster dose to Biocon's target price?The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...
- Biocon Biologics to offer 15% stake to Serum Institute Life SciencesUnder the alliance, BBL will get committed access to 100 million doses of vaccines annually for 15 years and commercialisation rights of th...
- Goldman Sachs buys stake in contract research firm Aragen Life SciencesAragen is a leading provider of outsourced discovery, development, and manufacturing services across both large and small molecule platform...
- Goldman Sachs set to buy 33% stake in GVK Bio at Rs 7,300-crore valuationThe other contenders included Carlyle Group, Warburg Pincus, General Atlantic and Quadria Capital, as well as Singapore’s Temasek Holdings.
- Market Movers: Voda slumps; Airtel, Biocon jump; sell signal in 269 stocksThe recent swing high of Nifty to 11,794 is unlikely to be breached on the upside in the short term. Immediate support is placed at 11,365.
- True North to acquire 2.4% stake in Biocon BiologicsDeal values Biocon Biologics at $3 billion
- Reduce corporate tax to 25% to kick-start investment: Kiran Mazumdar ShawQuick fixes needed so that short term demand can start kicking in, says Biocon CMD.
- Fifteen stocks in focus on Friday, 17 February 2017Foreign investors can now buy more shares in HDFC Bank as the Reserve Bank has removed restrictions imposed on it with immediate effect.
- Teva’s hostile bid for Mylan: Deal could open up a $2-billion opportunity for pharma companiesAccording to experts, there is a possibility that the fruition of the deal will open up a $2-billion opportunity for Indian generic pharma ...
Load More
